Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 674 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Edema Clear all
Terminated No phase listed Observational Results available

A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer

NCT01321697
View directory record Official record
Conditions
Vulvar Cancer
Interventions
Routine Leg edema and groin dissection
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO

NCT02387788
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
AKB-9778
Drug
Lead sponsor
Aerpio Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

NCT06011798
View directory record Official record
Conditions
Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
Interventions
Aflibercept, foselutoclax
Drug
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 29, 2026, 2:32 PM EDT
Not listed Phase 1 Interventional

Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms

NCT02403128
View directory record Official record
Conditions
Macular Edema, Retinal Artery Macroaneurysm
Interventions
aflibercept
Drug
Lead sponsor
Kamal Kishore, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Behavior and Exercise Versus Drug Treatment in Men With Nocturia (BEDTiMe)

NCT00824200
View directory record Official record
Conditions
Nocturia
Interventions
Behavioral, tamsulosin (alpha-adrenergic antagonist medication), placebo, placebo
Behavioral · Drug
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
40 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Not applicable Interventional

A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema

NCT00346138
View directory record Official record
Conditions
Fuchs Dystrophy, Corneal Edema
Interventions
Corneal transplantation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME

NCT02363621
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab 0.3 mg, Aflibercept 2.0 mg
Drug
Lead sponsor
Arshad Khanani
Other
Eligibility
21 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

NCT00089765
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 2:32 PM EDT
Completed No phase listed Observational Results available

Evaluation of Vitrectomy for Diabetic Macular Edema

NCT00709319
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
48
States / cities
Irvine, California • Loma Linda, California • Palm Springs, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 29, 2026, 2:32 PM EDT
Completed No phase listed Observational

Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis

NCT00001912
View directory record Official record
Conditions
Cysticercosis, Cysts, Seizures
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude

NCT02024386
View directory record Official record
Conditions
Hypertension, Pulmonary, Altitude Sickness
Interventions
Riociguat
Drug
Lead sponsor
Richard Moon
Other
Eligibility
18 Years to 40 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 29, 2026, 2:32 PM EDT
Completed No phase listed Observational

Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

NCT02000102
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Intravitreal Injection of Aflibercept
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 29, 2026, 2:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

NCT02338973
View directory record Official record
Conditions
Inherited Ophthalmic Diseases, Inherited Retinal Degeneration
Interventions
Interferon gamma-1b
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 29, 2026, 2:32 PM EDT
Enrolling by invitation No phase listed Observational

The BEACON Trial: Diagnostic Tools for Breast Lymphedema After Treatment for Breast Cancer

NCT06900023
View directory record Official record
Conditions
Breast Edema, Breast Lymphedema, Lymphedema, Breast Cancer, Lymphedema
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional

Sirolimus in Treating Patients With Glioblastoma Multiforme

NCT00047073
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Rapamycin, Surgery, Supportive Care
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 29, 2026, 2:32 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

NCT04362241
View directory record Official record
Conditions
Retinopathy, Diabetic
Interventions
Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Drug
Lead sponsor
Ophthalmic Consultants of the Capital Region
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Troy, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema

NCT00367133
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Standard of Care Group, 1mg triamcinolone acetonide, 4mg triamcinolone acetonide
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
84
States / cities
Little Rock, Arkansas • Baldwin Park, California • Beverly Hills, California + 67 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

NCT01571232
View directory record Official record
Conditions
Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Interventions
dexamethasone intravitreal implant, intravitreal bevacizumab
Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

NCT01319487
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
2304 Eye Drops High Dose, 2304 Eye Drops Low Dose, Placebo Eye Drops
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Phoenix, Arizona • Fort Myers, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Use of Pulsed Electromagnetic Fields (PEMF) After Breast Reconstruction Surgery

NCT01262599
View directory record Official record
Conditions
Other Reconstructive Surgery
Interventions
Sham PEMF Device, Ivivi Torino II PEMF Device
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 29, 2026, 2:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Evaluate the SENSE Device's Ability to Detect TBI

NCT06828107
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
SENSE device
Device
Lead sponsor
Sense Diagnostics, LLC
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Gainesville, Florida • Cincinnati, Ohio • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation

NCT00457145
View directory record Official record
Conditions
Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

NCT02302079
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Macular Edema
Interventions
ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection
Drug · Other
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 29, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema

NCT01934556
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation
Drug · Device
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Beverly Hills, California • West Columbia, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 29, 2026, 2:32 PM EDT